-
嗜铬细胞瘤(pheochromocytoma,PCC)是一种儿茶酚胺分泌异常的神经内分泌肿瘤(neuroendocrine tumor, NET),其发病较为罕见,大部分起源于肾上腺髓质中的嗜铬细胞,约有15%来源于肾上腺外的交感神经节,又被称为副神经节瘤(paraganglioma,PGL)。PCC的典型症状包括头痛、心悸、焦虑和发汗,常伴有继发性高血压,这些症状与血液中异常增高的儿茶酚胺浓度相关。长期的高儿茶酚胺血症将严重损害大脑、心脏、肾脏等靶器官的功能,严重者甚至危及生命,因此尽早确诊是治疗PCC的关键。随着技术的不断发展,放射性核素因具有功能显像及治疗两方面的作用而被越来越多地应用于PCC的诊疗过程中。笔者就放射性核素在PCC诊断与治疗中的应用进展综述如下。
放射性核素在嗜铬细胞瘤诊断与治疗中的应用进展
Advances in the application of radionuclide in the diagnosis and treatment of pheochromocytoma
-
摘要: 嗜铬细胞瘤(PCC)是一种罕见的神经内分泌肿瘤(NET),准确的定位诊断是进行治疗的关键。目前包括放射性碘标记的间碘苄胍(MIBG)扫描、PET、放射性核素标记的生长抑素类似物(SSTR)扫描等核医学功能显像对PCC的诊断有较高的价值。同时,放射性碘标记的MIBG及肽类受体介导的放射性核素治疗对于PCC的姑息性治疗也有一定价值。笔者对放射性核素在PCC诊断与治疗中的应用进行综述,以期为临床制定个性化治疗方案提供帮助。Abstract: Pheochromocytoma(PCC) is a rare neuroendocrine tumor(NET), and accurate diagnosis is the key to treatment. At present, including radioactive iodine markers of iodine benzyl(MIBG) guanidine scanning, positron emission tomography(PET), radioactive nuclide labeled somatostatin analogue nuclear medicine functions such as scanning imaging in the diagnosis of pheochromocytoma have higher value. At the same time, the radionuclide therapy mediated by iodide and peptide receptor also has certain value in the palliative treatment of pheochromocytoma. The application of radionuclides in the diagnosis and treatment of pheochromocytoma was reviewed in order to provide help for the development of individualized treatment.
-
Key words:
- Pheochromocytoma /
- 3-Iodobenzylguanidine /
- Positron emission tomography /
- Receptors, somatostatin /
- Therapy /
- Imaging
-
[1] Vallabhajosula S, Nikolopoulou A. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology[J]. Semin Nucl Med, 2011, 41(5): 324−333. DOI: 10.1053/j.semnuclmed.2011.05.003 [2] 董峰. 核素131I标记MIBG体内示踪诊断嗜铬细胞瘤[J]. 甘肃医药, 2012, 31(9): 678−679. DOI: 10.3969/j.issn.1004−2725.2012.09.017
Dong F. 131I-labeled MIBG in vivo tracer diagnosis of pheochromocytoma[J]. Gansu Med J, 2012, 31(9): 678−679. DOI: 10.3969/j.issn.1004−2725.2012.09.017[3] Wieland DM, Wu J, Brown LE, et al. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine[J]. J Nucl Med, 1980, 21(4):349-353.
[4] 张迎强, 陈黎波, 李方, 等. 131I-MIBG显像诊断嗜铬细胞瘤[J]. 中国医学影像技术, 2009, 25(7): 1283−1285. DOI: 10.3321/j.issn:1003−3289.2009.07.046
Zhang YQ, Chen LB, Li F, et al. Application of 131I-MIBG scintigraphy in diagnosis of pheochromocytoma[J]. Chin J Med Imaging Technol, 2009, 25(7): 1283−1285. DOI: 10.3321/j.issn:1003−3289.2009.07.046[5] Pappachan JM, Raskauskiene D, Sriraman R, et al. Diagnosis and management of pheochromocytoma: a practical guide to clinicians[J]. Curr Hypertens Rep, 2014, 16(7): 442. DOI: 10.1007/s11906−014−0442−z [6] Baez JC, Jagannathan JP, Krajewski K, et al. Pheochromocytoma and paraganglioma: imaging characteristics[J]. Cancer Imaging, 2012, 12: 153−162. DOI: 10.1102/1470−7330.2012.0016 [7] Tiwari A, Shah N, Sarathi V, et al. Genetic status determines 18F-FDG uptake in pheochromocytoma/paraganglioma[J]. J Med Imaging Radiat Oncol, 2017, 61(6): 745−752. DOI: 10.1111/1754−9485.12620 [8] Chang CA, Pattison DA, Tothill RW, et al. 68Ga-DOTATATE and 18F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity[J]. Cancer Imaging, 2016, 16: 22. DOI: 10.1186/s40644−016−0084−2 [9] Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma[J]. J Clin Oncol, 2007, 25(16): 2262−2269. DOI: 10.1200/JCO.2006.09.6297 [10] Fikri AS, Kroiss A, Ahmad Z, et al. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma(PCC/PGL)using 18F-FDG PET/CT[J]. Acta Radiologica, 2014, 55(5): 631−640. DOI: 10.1177/0284185113504330 [11] Pacak K, Eisenhofer G, Carrasquillo JA, et al. 6-[18F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma[J]. Hypertension, 2001, 38(1): 6−8. DOI: 10.1161/01.HYP.38.1.6 [12] Ilias I, Yu J, Carrasquillo JA, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus[131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma[J]. J Clin Endocrinol Metab, 2003, 88(9): 4083−4087. DOI: 10.1210/jc.2003−030235 [13] 林薇, 李红. 嗜铬细胞瘤定位核素诊断方法的研究进展[J]. 国际内分泌代谢杂志, 2006, 26(6): 418−420. DOI: 10.3760/cma.j.issn.1673−4157.2006.06.017
Lin W, Li H. The radionuclide imaging methods for the diagnostic localization of pheochromocytoma[J]. Int J Endocrinol Metab, 2006, 26(6): 418−420. DOI: 10.3760/cma.j.issn.1673−4157.2006.06.017[14] 贾丽娜, 张岚. 18F-DOPA制备研究进展[J]. 同位素, 2017, 30(1): 71−77. DOI: 10.7538/tws.2017.30.01.0071
Jia LN, Zhang L. Research Progress in the Preparation of 18F-DOPA[J]. Journal of Isotopes, 2017, 30(1): 71−77. DOI: 10.7538/tws.2017.30.01.0071[15] Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results[J]. Radiology, 2002, 222(2): 507−512. DOI: 10.1148/radiol.2222010622 [16] Zanzi I, Studentsova Y, Bjelke D, et al. Fluorine-18-fluorodihydroxyphenylalanine Positron-emission Tomography Scans of Neuroendocrine Tumors (Carcinoids and Pheochromocytomas)[J]. J Clin Imaging Sci, 2017, 7: 20. DOI: 10.4103/jcis.JCIS_107_16 [17] 景红丽, 李方. 生长抑素受体显像和治疗在神经内分泌肿瘤方面的临床应用[J]. 中国医学影像学杂志, 2004, 12(4): 296−299. DOI: 10.3969/j.issn.1005−5185.2004.04.019
Jing HL, Li F. Clinical application of somatostatin receptor imaging and therapy in neuroendocrine tumors[J]. Chinese J Med Imaging, 2004, 12(4): 296−299. DOI: 10.3969/j.issn.1005−5185.2004.04.019[18] 潘慧, 史轶蘩. 生长抑素受体显像在内分泌临床的应用[J]. 国外医学内分泌学分册, 2002, 22(5): 289−292. DOI: 10.3760/cma.j.issn.1673−4157.2002.05.011
Pan H, Shi YF. Clinical application of somatostatin receptor imaging in endocrine[J]. Section Endocrinol Foreign Med Sci, 2002, 22(5): 289−292. DOI: 10.3760/cma.j.issn.1673−4157.2002.05.011[19] van der Harst E, de Herder WW, Bruining HA, et al. [123I]metaiodobenzylguanidine and [111In]octreotide uptake in begnign and malignant pheochromocytomas[J]. J Clin Endocrinol Metab, 2001, 86(2): 685−693. DOI: 10.1210/jc.86.2.685 [20] 陈黎波, 李方, 景红丽, 等. 99Tcm-HTOC和131Ⅰ-MIBG显像诊断嗜铬细胞瘤的比较[J]. 中华核医学与分子影像杂志, 2006, 26(1): 26−28. DOI: 10.3760/cma.j.issn.2095−2848.2006.01.008
Chen LB, Li F, Jing HL, et al. A comparative study of 99Tcm-HTOC and 131I-MIBG in diagnosing pheochromocytoma[J]. Chin J Nucl Med, 2006, 26(1): 26−28. DOI: 10.3760/cma.j.issn.2095−2848.2006.01.008[21] 赵晓斌. 68Ga-DOTATATE和18F-FDG PET/CT显像在垂体瘤中的临床应用研究[D]. 北京: 北京协和医学院, 2014.
Zhao XB. Clinical application of 68Ga-DOTATATE and 18F-FDG PET/CT imaging in pituitary tumor[D]. Beijing: Peking Union Medical College, 2014.[22] Janssen I, Blanchet EM, Adams K, et al. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma[J]. Clin Cancer Res, 2015, 21(17): 3888−3895. DOI: 10.1158/1078−0432.CCR−14−2751 [23] Archier A, Varoquaux A, Garrigue P, et al. Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases[J]. Eur J Nucl Med Mol Imaging, 2016, 43(7): 1248−1257. DOI: 10.1007/s00259−015−3268−2 [24] 李方. 68Ga标记显像剂的发展: 核医学的进步与契机[J]. 中华核医学与分子影像杂志, 2017, 37(3): 129−131. DOI: 10.3760/cma.j.issn.2095−2848.2017.03.001
Li F. 68Ga-radiopharmacueticals development: advances and opportunities of nuclear medicine[J]. Chin J Nucl Med Mol Imaging, 2017, 37(3): 129−131. DOI: 10.3760/cma.j.issn.2095−2848.2017.03.001[25] 罗琼, 罗全勇, 朱瑞森, 等. 131I-间碘苄胍治疗94例恶性嗜铬细胞瘤转移灶25年随访的疗效评价[J]. 中国医药导报, 2011, 8(32): 29−30, 90. DOI: 10.3969/j.issn.1673−7210.2011.32.011
Luo Q, Luo QY, Zhu RS, et al. Efficacy evaluation of 25-year follow-up in 94 cases of malignant pheochromocytoma with metastases treated by 131I-meta-iodo benzyl guanidine[J]. China Medical Herald, 2011, 8(32): 29−30, 90. DOI: 10.3969/j.issn.1673−7210.2011.32.011[26] Rufini V, Treglia G, Perotti G, et al. The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas[J]. Hormones(Athens), 2013, 12(1): 58−68. [27] Sisson J, Shapiro B, Beierwaltes WH, et al. Treatment of malignant pheochromocytoma with a new radiopharmaceutical[J]. Trans Assoc Am Physicians, 1983, 96: 209−217. [28] Carrasquillo JA, Pandit-Taskar N, Chen CC. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma[J]. Semin Nucl Med, 2016, 46(3): 203−214. DOI: 10.1053/j.semnuclmed.2016.01.011 [29] Giammarile F, Chiti A, Lassmann M, et al. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-MIBG) therapy[J]. Eur J Nucl Med Mol Imaging, 2008, 35(5): 1039−1047. DOI: 10.1007/s00259−008−0715−3 [30] 中华医学会内分泌学分会肾上腺学组. 嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识[J]. 中华内分泌代谢杂志, 2016, 32(3): 181-187. DOI: 10.3760/cma.j.issn.1000-6699.2016.03.002.
Chinese Society of Endocrinology Adrenal Gland Group. Expert consensus on the diagnosis and treatment of pheochromocytoma and paraganglioma[J]. Chin J Endocrinol Metab, 2016, 32(3): 181-187. DOI: 10.3760/cma.j.issn.1000-6699.2016.03.002.[31] van Hulsteijn LT, Niemeijer ND, Dekkers OM, et al. 131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis[J]. Clin Endocrinol (Oxf), 2014, 80(4): 487−501. DOI: 10.1111/cen.12341 [32] 臧士明, 艾书跃, 姚晓晨, 等. 18F-FDG及68Ga-DOTA-NOC PET/CT对G3神经内分泌肿瘤的诊断比较[J]. 中华核医学与分子影像杂志, 2017, 37(4): 202−206. DOI: 10.3760/cma.j.issn.2095−2848.2017.04.003
Zang SM, Ai SY, Yao XC, et al. Comparison of 18F-FDG and 68Ga-DOTA-NOC PET/CT on the diagnosis of G3 neuroendocrine neoplasm[J]. Chin J Nucl Med Mol Imaging, 2017, 37(4): 202−206. DOI: 10.3760/cma.j.issn.2095−2848.2017.04.003[33] Pinato DJ, Black JR, Ramaswami R, et al. Peptide receptor radionuclide therapy for metastatic paragangliomas[J]. Med Oncol, 2016, 33(5): 47. DOI: 10.1007/s12032−016−0737−9
计量
- 文章访问数: 12664
- HTML全文浏览量: 11221
- PDF下载量: 26